A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
Retrospective Study Based on Somatic Mutations, Genetic Polymorphisms and Metabolomics Related to Individual Variations of Drug Effect and Adverse Drug Reaction of EGFR-TKIs,Gefitinib and Erlotinib in Non-small Cell Lung Cancer Treatment.
Sponsor: Sun Yat-sen University
Listed as NCT01994057, this observational or N/A phase trial focuses on EGFR-TKI Resistant Mutation and EGFR-TKI Sensitizing Mutation and remains actively recruiting participants. Sponsored by Sun Yat-sen University, it has been updated 14 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
May 2023 — Jul 2024 [monthly]
Recruiting
-
Nov 2022 — May 2023 [monthly]
Recruiting
-
Dec 2021 — Nov 2022 [monthly]
Recruiting
▶ Show 9 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Recruiting
-
Nov 2020 — Dec 2020 [monthly]
Recruiting
-
Sep 2019 — Nov 2020 [monthly]
Recruiting
-
Jun 2018 — Sep 2019 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Sep 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .